nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—PGR—breast cancer	0.0658	0.228	CbGaD
Levonorgestrel—SHBG—breast cancer	0.0615	0.213	CbGaD
Levonorgestrel—AR—breast cancer	0.054	0.187	CbGaD
Levonorgestrel—CYP19A1—breast cancer	0.0452	0.156	CbGaD
Levonorgestrel—ESR1—breast cancer	0.0416	0.144	CbGaD
Levonorgestrel—SHBG—Fluoxymesterone—breast cancer	0.0407	0.12	CbGbCtD
Levonorgestrel—CYP19A1—Exemestane—breast cancer	0.0345	0.101	CbGbCtD
Levonorgestrel—AR—Fluoxymesterone—breast cancer	0.0341	0.1	CbGbCtD
Levonorgestrel—Danazol—Fluoxymesterone—breast cancer	0.0323	0.161	CrCrCtD
Levonorgestrel—Testosterone—Exemestane—breast cancer	0.0296	0.148	CrCrCtD
Levonorgestrel—ESR1—Fluoxymesterone—breast cancer	0.0295	0.0867	CbGbCtD
Levonorgestrel—ESR1—Toremifene—breast cancer	0.0295	0.0867	CbGbCtD
Levonorgestrel—CYP19A1—Letrozole—breast cancer	0.0293	0.0863	CbGbCtD
Levonorgestrel—Norethindrone—Fluoxymesterone—breast cancer	0.0281	0.14	CrCrCtD
Levonorgestrel—ESR1—Fulvestrant—breast cancer	0.0274	0.0806	CbGbCtD
Levonorgestrel—CYP19A1—Anastrozole—breast cancer	0.0261	0.0769	CbGbCtD
Levonorgestrel—Testosterone Propionate—Fluoxymesterone—breast cancer	0.0237	0.118	CrCrCtD
Levonorgestrel—Progesterone—Fluoxymesterone—breast cancer	0.0237	0.118	CrCrCtD
Levonorgestrel—Methyltestosterone—Fluoxymesterone—breast cancer	0.0231	0.115	CrCrCtD
Levonorgestrel—CYP3A4—breast cancer	0.0212	0.0733	CbGaD
Levonorgestrel—Testosterone—Fluoxymesterone—breast cancer	0.0205	0.103	CrCrCtD
Levonorgestrel—Hydrocortisone—Fluoxymesterone—breast cancer	0.0193	0.0963	CrCrCtD
Levonorgestrel—ESR1—Raloxifene—breast cancer	0.0163	0.048	CbGbCtD
Levonorgestrel—CYP19A1—Raloxifene—breast cancer	0.0132	0.0389	CbGbCtD
Levonorgestrel—ESR1—Tamoxifen—breast cancer	0.0108	0.0317	CbGbCtD
Levonorgestrel—CYP19A1—Tamoxifen—breast cancer	0.00872	0.0257	CbGbCtD
Levonorgestrel—CYP19A1—Paclitaxel—breast cancer	0.00679	0.02	CbGbCtD
Levonorgestrel—CYP3A4—Exemestane—breast cancer	0.00436	0.0129	CbGbCtD
Levonorgestrel—PGR—corpus luteum—breast cancer	0.00436	0.168	CbGeAlD
Levonorgestrel—CYP19A1—corpus luteum—breast cancer	0.00392	0.152	CbGeAlD
Levonorgestrel—CYP3A4—Letrozole—breast cancer	0.00371	0.0109	CbGbCtD
Levonorgestrel—CYP3A4—Anastrozole—breast cancer	0.00331	0.00974	CbGbCtD
Levonorgestrel—CYP3A4—Toremifene—breast cancer	0.00303	0.00891	CbGbCtD
Levonorgestrel—CYP3A4—Fulvestrant—breast cancer	0.00281	0.00828	CbGbCtD
Levonorgestrel—CYP3A4—Thiotepa—breast cancer	0.00251	0.00738	CbGbCtD
Levonorgestrel—CYP3A4—Ixabepilone—breast cancer	0.00229	0.00675	CbGbCtD
Levonorgestrel—CYP3A4—Lapatinib—breast cancer	0.00221	0.0065	CbGbCtD
Levonorgestrel—CYP3A4—Raloxifene—breast cancer	0.00167	0.00492	CbGbCtD
Levonorgestrel—CYP3A4—Vinorelbine—breast cancer	0.00122	0.0036	CbGbCtD
Levonorgestrel—CYP3A4—Tamoxifen—breast cancer	0.00111	0.00325	CbGbCtD
Levonorgestrel—CYP3A4—Mitoxantrone—breast cancer	0.00108	0.00317	CbGbCtD
Levonorgestrel—CYP3A4—Paclitaxel—breast cancer	0.00086	0.00253	CbGbCtD
Levonorgestrel—SRD5A1—female reproductive system—breast cancer	0.000852	0.0329	CbGeAlD
Levonorgestrel—CYP3A4—Irinotecan—breast cancer	0.000849	0.0025	CbGbCtD
Levonorgestrel—SRD5A1—adrenal gland—breast cancer	0.000832	0.0321	CbGeAlD
Levonorgestrel—CYP3A4—Vinblastine—breast cancer	0.000754	0.00222	CbGbCtD
Levonorgestrel—SRD5A1—endocrine gland—breast cancer	0.000721	0.0279	CbGeAlD
Levonorgestrel—PGR—mammary gland—breast cancer	0.000676	0.0261	CbGeAlD
Levonorgestrel—CYP3A4—Docetaxel—breast cancer	0.000622	0.00183	CbGbCtD
Levonorgestrel—PGR—nipple—breast cancer	0.000559	0.0216	CbGeAlD
Levonorgestrel—ESR1—mammary gland—breast cancer	0.000528	0.0204	CbGeAlD
Levonorgestrel—CYP3A4—Doxorubicin—breast cancer	0.000464	0.00136	CbGbCtD
Levonorgestrel—AR—nipple—breast cancer	0.000445	0.0172	CbGeAlD
Levonorgestrel—PGR—epithelium—breast cancer	0.000376	0.0145	CbGeAlD
Levonorgestrel—SHBG—endometrium—breast cancer	0.000375	0.0145	CbGeAlD
Levonorgestrel—ESR1—embryo—breast cancer	0.000361	0.0139	CbGeAlD
Levonorgestrel—SHBG—uterus—breast cancer	0.000345	0.0133	CbGeAlD
Levonorgestrel—SHBG—pituitary gland—breast cancer	0.000339	0.0131	CbGeAlD
Levonorgestrel—SHBG—adipose tissue—breast cancer	0.000338	0.013	CbGeAlD
Levonorgestrel—PGR—endometrium—breast cancer	0.000337	0.013	CbGeAlD
Levonorgestrel—PGR—uterus—breast cancer	0.000311	0.012	CbGeAlD
Levonorgestrel—SHBG—female reproductive system—breast cancer	0.00031	0.012	CbGeAlD
Levonorgestrel—PGR—pituitary gland—breast cancer	0.000305	0.0118	CbGeAlD
Levonorgestrel—PGR—adipose tissue—breast cancer	0.000304	0.0117	CbGeAlD
Levonorgestrel—CYP19A1—endometrium—breast cancer	0.000304	0.0117	CbGeAlD
Levonorgestrel—SHBG—adrenal gland—breast cancer	0.000303	0.0117	CbGeAlD
Levonorgestrel—AR—epithelium—breast cancer	0.0003	0.0116	CbGeAlD
Levonorgestrel—ESR1—epithelium—breast cancer	0.000294	0.0114	CbGeAlD
Levonorgestrel—SHBG—bone marrow—breast cancer	0.000293	0.0113	CbGeAlD
Levonorgestrel—AR—skin of body—breast cancer	0.000285	0.011	CbGeAlD
Levonorgestrel—SHBG—female gonad—breast cancer	0.000282	0.0109	CbGeAlD
Levonorgestrel—CYP19A1—uterus—breast cancer	0.00028	0.0108	CbGeAlD
Levonorgestrel—PGR—female reproductive system—breast cancer	0.00028	0.0108	CbGeAlD
Levonorgestrel—CYP19A1—adipose tissue—breast cancer	0.000274	0.0106	CbGeAlD
Levonorgestrel—PGR—adrenal gland—breast cancer	0.000273	0.0105	CbGeAlD
Levonorgestrel—AR—endometrium—breast cancer	0.000269	0.0104	CbGeAlD
Levonorgestrel—ESR1—endometrium—breast cancer	0.000264	0.0102	CbGeAlD
Levonorgestrel—SHBG—endocrine gland—breast cancer	0.000263	0.0101	CbGeAlD
Levonorgestrel—PGR—female gonad—breast cancer	0.000254	0.00983	CbGeAlD
Levonorgestrel—CYP19A1—female reproductive system—breast cancer	0.000252	0.00972	CbGeAlD
Levonorgestrel—AR—uterus—breast cancer	0.000248	0.00957	CbGeAlD
Levonorgestrel—CYP19A1—adrenal gland—breast cancer	0.000245	0.00948	CbGeAlD
Levonorgestrel—AR—pituitary gland—breast cancer	0.000243	0.0094	CbGeAlD
Levonorgestrel—ESR1—uterus—breast cancer	0.000243	0.00939	CbGeAlD
Levonorgestrel—AR—adipose tissue—breast cancer	0.000242	0.00936	CbGeAlD
Levonorgestrel—ESR1—pituitary gland—breast cancer	0.000239	0.00923	CbGeAlD
Levonorgestrel—ESR1—adipose tissue—breast cancer	0.000238	0.00919	CbGeAlD
Levonorgestrel—PGR—endocrine gland—breast cancer	0.000237	0.00914	CbGeAlD
Levonorgestrel—CYP19A1—female gonad—breast cancer	0.000229	0.00884	CbGeAlD
Levonorgestrel—AR—female reproductive system—breast cancer	0.000223	0.0086	CbGeAlD
Levonorgestrel—ESR1—female reproductive system—breast cancer	0.000219	0.00845	CbGeAlD
Levonorgestrel—AR—adrenal gland—breast cancer	0.000217	0.0084	CbGeAlD
Levonorgestrel—ESR1—adrenal gland—breast cancer	0.000213	0.00824	CbGeAlD
Levonorgestrel—CYP19A1—endocrine gland—breast cancer	0.000213	0.00822	CbGeAlD
Levonorgestrel—AR—female gonad—breast cancer	0.000203	0.00783	CbGeAlD
Levonorgestrel—ESR1—female gonad—breast cancer	0.000199	0.00768	CbGeAlD
Levonorgestrel—AR—endocrine gland—breast cancer	0.000188	0.00728	CbGeAlD
Levonorgestrel—ESR1—endocrine gland—breast cancer	0.000185	0.00715	CbGeAlD
Levonorgestrel—PGR—lymph node—breast cancer	0.000164	0.00632	CbGeAlD
Levonorgestrel—CYP19A1—lymph node—breast cancer	0.000147	0.00568	CbGeAlD
Levonorgestrel—AR—lymph node—breast cancer	0.00013	0.00503	CbGeAlD
Levonorgestrel—ESR1—lymph node—breast cancer	0.000128	0.00494	CbGeAlD
Levonorgestrel—CYP3A4—female reproductive system—breast cancer	0.000122	0.00471	CbGeAlD
Levonorgestrel—Ethynodiol—PGR—breast cancer	0.000106	0.0386	CrCbGaD
Levonorgestrel—CYP3A4—endocrine gland—breast cancer	0.000103	0.00399	CbGeAlD
Levonorgestrel—Norelgestromin—PGR—breast cancer	0.0001	0.0364	CrCbGaD
Levonorgestrel—Allylestrenol—PGR—breast cancer	0.0001	0.0364	CrCbGaD
Levonorgestrel—Desogestrel—PGR—breast cancer	9.62e-05	0.0351	CrCbGaD
Levonorgestrel—Norgestimate—PGR—breast cancer	9e-05	0.0328	CrCbGaD
Levonorgestrel—Desogestrel—SHBG—breast cancer	8.99e-05	0.0328	CrCbGaD
Levonorgestrel—Nandrolone phenpropionate—AR—breast cancer	8.96e-05	0.0326	CrCbGaD
Levonorgestrel—Quinestrol—ESR1—breast cancer	8.11e-05	0.0296	CrCbGaD
Levonorgestrel—Etonogestrel—PGR—breast cancer	7.79e-05	0.0284	CrCbGaD
Levonorgestrel—Testosterone Propionate—CYP17A1—breast cancer	7.64e-05	0.0278	CrCbGaD
Levonorgestrel—Nandrolone phenpropionate—CYP19A1—breast cancer	7.5e-05	0.0273	CrCbGaD
Levonorgestrel—Etonogestrel—SHBG—breast cancer	7.28e-05	0.0265	CrCbGaD
Levonorgestrel—Nandrolone decanoate—AR—breast cancer	6.79e-05	0.0247	CrCbGaD
Levonorgestrel—Ethynodiol—ESR1—breast cancer	6.68e-05	0.0243	CrCbGaD
Levonorgestrel—Allylestrenol—ESR1—breast cancer	6.31e-05	0.023	CrCbGaD
Levonorgestrel—Testosterone Propionate—COMT—breast cancer	6.23e-05	0.0227	CrCbGaD
Levonorgestrel—Mestranol—ESR1—breast cancer	6.15e-05	0.0224	CrCbGaD
Levonorgestrel—Desogestrel—ESR1—breast cancer	6.07e-05	0.0221	CrCbGaD
Levonorgestrel—Norgestimate—ESR1—breast cancer	5.68e-05	0.0207	CrCbGaD
Levonorgestrel—Nandrolone decanoate—CYP19A1—breast cancer	5.68e-05	0.0207	CrCbGaD
Levonorgestrel—Danazol—PGR—breast cancer	5.02e-05	0.0183	CrCbGaD
Levonorgestrel—Etonogestrel—ESR1—breast cancer	4.92e-05	0.0179	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ESR2—breast cancer	4.76e-05	0.0173	CrCbGaD
Levonorgestrel—Danazol—SHBG—breast cancer	4.69e-05	0.0171	CrCbGaD
Levonorgestrel—Testosterone Propionate—AR—breast cancer	4.64e-05	0.0169	CrCbGaD
Levonorgestrel—Norethindrone—PGR—breast cancer	4.46e-05	0.0163	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—SHBG—breast cancer	4.34e-05	0.0158	CrCbGaD
Levonorgestrel—Norethindrone—SHBG—breast cancer	4.17e-05	0.0152	CrCbGaD
Levonorgestrel—Danazol—AR—breast cancer	4.11e-05	0.015	CrCbGaD
Levonorgestrel—Methyltestosterone—SHBG—breast cancer	3.96e-05	0.0144	CrCbGaD
Levonorgestrel—Progesterone—CYP17A1—breast cancer	3.51e-05	0.0128	CrCbGaD
Levonorgestrel—Methyltestosterone—AR—breast cancer	3.47e-05	0.0127	CrCbGaD
Levonorgestrel—Danazol—CYP19A1—breast cancer	3.44e-05	0.0125	CrCbGaD
Levonorgestrel—Allylestrenol—CYP3A4—breast cancer	3.22e-05	0.0117	CrCbGaD
Levonorgestrel—Progesterone—ABCC1—breast cancer	3.18e-05	0.0116	CrCbGaD
Levonorgestrel—Danazol—ESR1—breast cancer	3.17e-05	0.0115	CrCbGaD
Levonorgestrel—Hydrocortisone—SHBG—breast cancer	2.98e-05	0.0109	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ESR1—breast cancer	2.93e-05	0.0107	CrCbGaD
Levonorgestrel—Methyltestosterone—CYP19A1—breast cancer	2.91e-05	0.0106	CrCbGaD
Levonorgestrel—Progesterone—PGR—breast cancer	2.6e-05	0.00948	CrCbGaD
Levonorgestrel—Etonogestrel—CYP3A4—breast cancer	2.51e-05	0.00914	CrCbGaD
Levonorgestrel—Progesterone—SHBG—breast cancer	2.43e-05	0.00886	CrCbGaD
Levonorgestrel—Progesterone—CYP1B1—breast cancer	2.43e-05	0.00886	CrCbGaD
Levonorgestrel—Testosterone—SHBG—breast cancer	2.3e-05	0.00837	CrCbGaD
Levonorgestrel—Testosterone—CYP1B1—breast cancer	2.3e-05	0.00837	CrCbGaD
Levonorgestrel—Progesterone—AR—breast cancer	2.13e-05	0.00777	CrCbGaD
Levonorgestrel—Hydrocortisone—ABCG2—breast cancer	2.06e-05	0.0075	CrCbGaD
Levonorgestrel—Testosterone—AR—breast cancer	2.02e-05	0.00734	CrCbGaD
Levonorgestrel—Testosterone—CYP19A1—breast cancer	1.69e-05	0.00615	CrCbGaD
Levonorgestrel—Progesterone—ESR1—breast cancer	1.64e-05	0.00598	CrCbGaD
Levonorgestrel—Danazol—CYP3A4—breast cancer	1.62e-05	0.00589	CrCbGaD
Levonorgestrel—Testosterone—ABCG2—breast cancer	1.58e-05	0.00577	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—CYP3A4—breast cancer	1.5e-05	0.00545	CrCbGaD
Levonorgestrel—Body temperature increased—Paclitaxel—breast cancer	1.48e-05	0.000168	CcSEcCtD
Levonorgestrel—Abdominal pain—Paclitaxel—breast cancer	1.48e-05	0.000168	CcSEcCtD
Levonorgestrel—Urethral disorder—Epirubicin—breast cancer	1.48e-05	0.000167	CcSEcCtD
Levonorgestrel—Anorexia—Capecitabine—breast cancer	1.47e-05	0.000166	CcSEcCtD
Levonorgestrel—Vomiting—Irinotecan—breast cancer	1.46e-05	0.000165	CcSEcCtD
Levonorgestrel—Vomiting—Mitoxantrone—breast cancer	1.46e-05	0.000165	CcSEcCtD
Levonorgestrel—Sinusitis—Doxorubicin—breast cancer	1.46e-05	0.000165	CcSEcCtD
Levonorgestrel—Immune system disorder—Methotrexate—breast cancer	1.46e-05	0.000165	CcSEcCtD
Levonorgestrel—Dizziness—Fluorouracil—breast cancer	1.46e-05	0.000165	CcSEcCtD
Levonorgestrel—Visual impairment—Epirubicin—breast cancer	1.46e-05	0.000165	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Methotrexate—breast cancer	1.45e-05	0.000164	CcSEcCtD
Levonorgestrel—Rash—Mitoxantrone—breast cancer	1.45e-05	0.000164	CcSEcCtD
Levonorgestrel—Rash—Irinotecan—breast cancer	1.45e-05	0.000164	CcSEcCtD
Levonorgestrel—Dermatitis—Irinotecan—breast cancer	1.45e-05	0.000164	CcSEcCtD
Levonorgestrel—Dermatitis—Mitoxantrone—breast cancer	1.45e-05	0.000164	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Docetaxel—breast cancer	1.45e-05	0.000164	CcSEcCtD
Levonorgestrel—Headache—Irinotecan—breast cancer	1.44e-05	0.000163	CcSEcCtD
Levonorgestrel—Headache—Mitoxantrone—breast cancer	1.44e-05	0.000163	CcSEcCtD
Levonorgestrel—Insomnia—Docetaxel—breast cancer	1.44e-05	0.000163	CcSEcCtD
Levonorgestrel—Norethindrone—CYP3A4—breast cancer	1.44e-05	0.00524	CrCbGaD
Levonorgestrel—Erythema multiforme—Epirubicin—breast cancer	1.43e-05	0.000161	CcSEcCtD
Levonorgestrel—Alopecia—Methotrexate—breast cancer	1.43e-05	0.000161	CcSEcCtD
Levonorgestrel—Vomiting—Gemcitabine—breast cancer	1.43e-05	0.000161	CcSEcCtD
Levonorgestrel—Dyspnoea—Docetaxel—breast cancer	1.42e-05	0.00016	CcSEcCtD
Levonorgestrel—Somnolence—Docetaxel—breast cancer	1.41e-05	0.00016	CcSEcCtD
Levonorgestrel—Mental disorder—Methotrexate—breast cancer	1.41e-05	0.00016	CcSEcCtD
Levonorgestrel—Rash—Gemcitabine—breast cancer	1.41e-05	0.00016	CcSEcCtD
Levonorgestrel—Dermatitis—Gemcitabine—breast cancer	1.41e-05	0.00016	CcSEcCtD
Levonorgestrel—Eye disorder—Epirubicin—breast cancer	1.41e-05	0.00016	CcSEcCtD
Levonorgestrel—Erythema—Methotrexate—breast cancer	1.41e-05	0.000159	CcSEcCtD
Levonorgestrel—Malnutrition—Methotrexate—breast cancer	1.41e-05	0.000159	CcSEcCtD
Levonorgestrel—Haemoglobin—Doxorubicin—breast cancer	1.4e-05	0.000159	CcSEcCtD
Levonorgestrel—Headache—Gemcitabine—breast cancer	1.4e-05	0.000159	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Capecitabine—breast cancer	1.4e-05	0.000159	CcSEcCtD
Levonorgestrel—Cardiac disorder—Epirubicin—breast cancer	1.4e-05	0.000159	CcSEcCtD
Levonorgestrel—Vomiting—Fluorouracil—breast cancer	1.4e-05	0.000158	CcSEcCtD
Levonorgestrel—Rhinitis—Doxorubicin—breast cancer	1.4e-05	0.000158	CcSEcCtD
Levonorgestrel—Dyspepsia—Docetaxel—breast cancer	1.4e-05	0.000158	CcSEcCtD
Levonorgestrel—Haemorrhage—Doxorubicin—breast cancer	1.4e-05	0.000158	CcSEcCtD
Levonorgestrel—Insomnia—Capecitabine—breast cancer	1.39e-05	0.000158	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Doxorubicin—breast cancer	1.39e-05	0.000157	CcSEcCtD
Levonorgestrel—Rash—Fluorouracil—breast cancer	1.39e-05	0.000157	CcSEcCtD
Levonorgestrel—Dermatitis—Fluorouracil—breast cancer	1.39e-05	0.000157	CcSEcCtD
Levonorgestrel—Pharyngitis—Doxorubicin—breast cancer	1.39e-05	0.000157	CcSEcCtD
Levonorgestrel—Decreased appetite—Docetaxel—breast cancer	1.38e-05	0.000156	CcSEcCtD
Levonorgestrel—Hypersensitivity—Paclitaxel—breast cancer	1.38e-05	0.000156	CcSEcCtD
Levonorgestrel—Headache—Fluorouracil—breast cancer	1.38e-05	0.000156	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Doxorubicin—breast cancer	1.38e-05	0.000156	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Docetaxel—breast cancer	1.37e-05	0.000155	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Doxorubicin—breast cancer	1.37e-05	0.000155	CcSEcCtD
Levonorgestrel—Dyspnoea—Capecitabine—breast cancer	1.37e-05	0.000155	CcSEcCtD
Levonorgestrel—Fatigue—Docetaxel—breast cancer	1.37e-05	0.000155	CcSEcCtD
Levonorgestrel—Urethral disorder—Doxorubicin—breast cancer	1.37e-05	0.000155	CcSEcCtD
Levonorgestrel—Nausea—Irinotecan—breast cancer	1.37e-05	0.000155	CcSEcCtD
Levonorgestrel—Nausea—Mitoxantrone—breast cancer	1.37e-05	0.000155	CcSEcCtD
Levonorgestrel—Methyltestosterone—CYP3A4—breast cancer	1.37e-05	0.00498	CrCbGaD
Levonorgestrel—Immune system disorder—Epirubicin—breast cancer	1.36e-05	0.000154	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Epirubicin—breast cancer	1.36e-05	0.000154	CcSEcCtD
Levonorgestrel—Constipation—Docetaxel—breast cancer	1.36e-05	0.000154	CcSEcCtD
Levonorgestrel—Pain—Docetaxel—breast cancer	1.36e-05	0.000154	CcSEcCtD
Levonorgestrel—Back pain—Methotrexate—breast cancer	1.36e-05	0.000154	CcSEcCtD
Levonorgestrel—Dyspepsia—Capecitabine—breast cancer	1.36e-05	0.000153	CcSEcCtD
Levonorgestrel—Arrhythmia—Epirubicin—breast cancer	1.35e-05	0.000153	CcSEcCtD
Levonorgestrel—Visual impairment—Doxorubicin—breast cancer	1.35e-05	0.000152	CcSEcCtD
Levonorgestrel—Asthenia—Paclitaxel—breast cancer	1.35e-05	0.000152	CcSEcCtD
Levonorgestrel—Decreased appetite—Capecitabine—breast cancer	1.34e-05	0.000151	CcSEcCtD
Levonorgestrel—Alopecia—Epirubicin—breast cancer	1.34e-05	0.000151	CcSEcCtD
Levonorgestrel—Nausea—Gemcitabine—breast cancer	1.33e-05	0.000151	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Capecitabine—breast cancer	1.33e-05	0.00015	CcSEcCtD
Levonorgestrel—Fatigue—Capecitabine—breast cancer	1.33e-05	0.00015	CcSEcCtD
Levonorgestrel—Pruritus—Paclitaxel—breast cancer	1.33e-05	0.00015	CcSEcCtD
Levonorgestrel—Mental disorder—Epirubicin—breast cancer	1.32e-05	0.00015	CcSEcCtD
Levonorgestrel—Erythema multiforme—Doxorubicin—breast cancer	1.32e-05	0.000149	CcSEcCtD
Levonorgestrel—Constipation—Capecitabine—breast cancer	1.32e-05	0.000149	CcSEcCtD
Levonorgestrel—Pain—Capecitabine—breast cancer	1.32e-05	0.000149	CcSEcCtD
Levonorgestrel—Malnutrition—Epirubicin—breast cancer	1.32e-05	0.000149	CcSEcCtD
Levonorgestrel—Erythema—Epirubicin—breast cancer	1.32e-05	0.000149	CcSEcCtD
Levonorgestrel—Progesterone—CYP1A1—breast cancer	1.31e-05	0.00478	CrCbGaD
Levonorgestrel—Nausea—Fluorouracil—breast cancer	1.31e-05	0.000148	CcSEcCtD
Levonorgestrel—Eye disorder—Doxorubicin—breast cancer	1.31e-05	0.000148	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Docetaxel—breast cancer	1.3e-05	0.000147	CcSEcCtD
Levonorgestrel—Anaemia—Methotrexate—breast cancer	1.3e-05	0.000147	CcSEcCtD
Levonorgestrel—Cardiac disorder—Doxorubicin—breast cancer	1.3e-05	0.000147	CcSEcCtD
Levonorgestrel—Flatulence—Epirubicin—breast cancer	1.3e-05	0.000147	CcSEcCtD
Levonorgestrel—Tension—Epirubicin—breast cancer	1.29e-05	0.000146	CcSEcCtD
Levonorgestrel—Diarrhoea—Paclitaxel—breast cancer	1.28e-05	0.000145	CcSEcCtD
Levonorgestrel—Nervousness—Epirubicin—breast cancer	1.28e-05	0.000144	CcSEcCtD
Levonorgestrel—Back pain—Epirubicin—breast cancer	1.27e-05	0.000144	CcSEcCtD
Levonorgestrel—Muscle spasms—Epirubicin—breast cancer	1.26e-05	0.000143	CcSEcCtD
Levonorgestrel—Immune system disorder—Doxorubicin—breast cancer	1.26e-05	0.000143	CcSEcCtD
Levonorgestrel—Vertigo—Methotrexate—breast cancer	1.26e-05	0.000143	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Capecitabine—breast cancer	1.26e-05	0.000142	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Doxorubicin—breast cancer	1.26e-05	0.000142	CcSEcCtD
Levonorgestrel—Abdominal pain—Docetaxel—breast cancer	1.26e-05	0.000142	CcSEcCtD
Levonorgestrel—Body temperature increased—Docetaxel—breast cancer	1.26e-05	0.000142	CcSEcCtD
Levonorgestrel—Norethindrone—ALB—breast cancer	1.25e-05	0.00457	CrCbGaD
Levonorgestrel—Arrhythmia—Doxorubicin—breast cancer	1.25e-05	0.000141	CcSEcCtD
Levonorgestrel—Ethinyl Estradiol—ABCB1—breast cancer	1.25e-05	0.00454	CrCbGaD
Levonorgestrel—Dizziness—Paclitaxel—breast cancer	1.24e-05	0.00014	CcSEcCtD
Levonorgestrel—Testosterone—CYP1A1—breast cancer	1.24e-05	0.00452	CrCbGaD
Levonorgestrel—Alopecia—Doxorubicin—breast cancer	1.24e-05	0.00014	CcSEcCtD
Levonorgestrel—Cough—Methotrexate—breast cancer	1.23e-05	0.000139	CcSEcCtD
Levonorgestrel—Mental disorder—Doxorubicin—breast cancer	1.22e-05	0.000138	CcSEcCtD
Levonorgestrel—Urticaria—Capecitabine—breast cancer	1.22e-05	0.000138	CcSEcCtD
Levonorgestrel—Abdominal pain—Capecitabine—breast cancer	1.22e-05	0.000138	CcSEcCtD
Levonorgestrel—Body temperature increased—Capecitabine—breast cancer	1.22e-05	0.000138	CcSEcCtD
Levonorgestrel—Malnutrition—Doxorubicin—breast cancer	1.22e-05	0.000138	CcSEcCtD
Levonorgestrel—Erythema—Doxorubicin—breast cancer	1.22e-05	0.000138	CcSEcCtD
Levonorgestrel—Anaemia—Epirubicin—breast cancer	1.22e-05	0.000137	CcSEcCtD
Levonorgestrel—Flatulence—Doxorubicin—breast cancer	1.2e-05	0.000136	CcSEcCtD
Levonorgestrel—Norethindrone—ABCB1—breast cancer	1.2e-05	0.00436	CrCbGaD
Levonorgestrel—Chest pain—Methotrexate—breast cancer	1.2e-05	0.000135	CcSEcCtD
Levonorgestrel—Myalgia—Methotrexate—breast cancer	1.2e-05	0.000135	CcSEcCtD
Levonorgestrel—Tension—Doxorubicin—breast cancer	1.19e-05	0.000135	CcSEcCtD
Levonorgestrel—Vomiting—Paclitaxel—breast cancer	1.19e-05	0.000135	CcSEcCtD
Levonorgestrel—Methyltestosterone—ALB—breast cancer	1.19e-05	0.00434	CrCbGaD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.19e-05	0.000134	CcSEcCtD
Levonorgestrel—Rash—Paclitaxel—breast cancer	1.18e-05	0.000134	CcSEcCtD
Levonorgestrel—Dermatitis—Paclitaxel—breast cancer	1.18e-05	0.000134	CcSEcCtD
Levonorgestrel—Discomfort—Methotrexate—breast cancer	1.18e-05	0.000134	CcSEcCtD
Levonorgestrel—Nervousness—Doxorubicin—breast cancer	1.18e-05	0.000134	CcSEcCtD
Levonorgestrel—Vertigo—Epirubicin—breast cancer	1.18e-05	0.000134	CcSEcCtD
Levonorgestrel—Syncope—Epirubicin—breast cancer	1.18e-05	0.000133	CcSEcCtD
Levonorgestrel—Back pain—Doxorubicin—breast cancer	1.18e-05	0.000133	CcSEcCtD
Levonorgestrel—Headache—Paclitaxel—breast cancer	1.18e-05	0.000133	CcSEcCtD
Levonorgestrel—Hypersensitivity—Docetaxel—breast cancer	1.17e-05	0.000133	CcSEcCtD
Levonorgestrel—Muscle spasms—Doxorubicin—breast cancer	1.17e-05	0.000132	CcSEcCtD
Levonorgestrel—Palpitations—Epirubicin—breast cancer	1.16e-05	0.000131	CcSEcCtD
Levonorgestrel—Loss of consciousness—Epirubicin—breast cancer	1.16e-05	0.000131	CcSEcCtD
Levonorgestrel—Cough—Epirubicin—breast cancer	1.15e-05	0.00013	CcSEcCtD
Levonorgestrel—Asthenia—Docetaxel—breast cancer	1.14e-05	0.000129	CcSEcCtD
Levonorgestrel—Infection—Methotrexate—breast cancer	1.14e-05	0.000129	CcSEcCtD
Levonorgestrel—Hypertension—Epirubicin—breast cancer	1.14e-05	0.000128	CcSEcCtD
Levonorgestrel—Hypersensitivity—Capecitabine—breast cancer	1.14e-05	0.000128	CcSEcCtD
Levonorgestrel—Pruritus—Docetaxel—breast cancer	1.13e-05	0.000127	CcSEcCtD
Levonorgestrel—Nervous system disorder—Methotrexate—breast cancer	1.12e-05	0.000127	CcSEcCtD
Levonorgestrel—Anaemia—Doxorubicin—breast cancer	1.12e-05	0.000127	CcSEcCtD
Levonorgestrel—Chest pain—Epirubicin—breast cancer	1.12e-05	0.000127	CcSEcCtD
Levonorgestrel—Myalgia—Epirubicin—breast cancer	1.12e-05	0.000127	CcSEcCtD
Levonorgestrel—Anxiety—Epirubicin—breast cancer	1.12e-05	0.000126	CcSEcCtD
Levonorgestrel—Nausea—Paclitaxel—breast cancer	1.12e-05	0.000126	CcSEcCtD
Levonorgestrel—Skin disorder—Methotrexate—breast cancer	1.11e-05	0.000126	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.11e-05	0.000126	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Methotrexate—breast cancer	1.11e-05	0.000125	CcSEcCtD
Levonorgestrel—Discomfort—Epirubicin—breast cancer	1.11e-05	0.000125	CcSEcCtD
Levonorgestrel—Asthenia—Capecitabine—breast cancer	1.11e-05	0.000125	CcSEcCtD
Levonorgestrel—Vertigo—Doxorubicin—breast cancer	1.09e-05	0.000124	CcSEcCtD
Levonorgestrel—Anorexia—Methotrexate—breast cancer	1.09e-05	0.000124	CcSEcCtD
Levonorgestrel—Syncope—Doxorubicin—breast cancer	1.09e-05	0.000123	CcSEcCtD
Levonorgestrel—Pruritus—Capecitabine—breast cancer	1.09e-05	0.000123	CcSEcCtD
Levonorgestrel—Diarrhoea—Docetaxel—breast cancer	1.09e-05	0.000123	CcSEcCtD
Levonorgestrel—Palpitations—Doxorubicin—breast cancer	1.08e-05	0.000122	CcSEcCtD
Levonorgestrel—Oedema—Epirubicin—breast cancer	1.07e-05	0.000121	CcSEcCtD
Levonorgestrel—Loss of consciousness—Doxorubicin—breast cancer	1.07e-05	0.000121	CcSEcCtD
Levonorgestrel—Infection—Epirubicin—breast cancer	1.07e-05	0.000121	CcSEcCtD
Levonorgestrel—Cough—Doxorubicin—breast cancer	1.06e-05	0.00012	CcSEcCtD
Levonorgestrel—Shock—Epirubicin—breast cancer	1.06e-05	0.000119	CcSEcCtD
Levonorgestrel—Diarrhoea—Capecitabine—breast cancer	1.05e-05	0.000119	CcSEcCtD
Levonorgestrel—Nervous system disorder—Epirubicin—breast cancer	1.05e-05	0.000119	CcSEcCtD
Levonorgestrel—Dizziness—Docetaxel—breast cancer	1.05e-05	0.000119	CcSEcCtD
Levonorgestrel—Hypertension—Doxorubicin—breast cancer	1.05e-05	0.000119	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Methotrexate—breast cancer	1.04e-05	0.000118	CcSEcCtD
Levonorgestrel—Skin disorder—Epirubicin—breast cancer	1.04e-05	0.000118	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Epirubicin—breast cancer	1.04e-05	0.000117	CcSEcCtD
Levonorgestrel—Insomnia—Methotrexate—breast cancer	1.04e-05	0.000117	CcSEcCtD
Levonorgestrel—Chest pain—Doxorubicin—breast cancer	1.04e-05	0.000117	CcSEcCtD
Levonorgestrel—Myalgia—Doxorubicin—breast cancer	1.04e-05	0.000117	CcSEcCtD
Levonorgestrel—Anxiety—Doxorubicin—breast cancer	1.03e-05	0.000117	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.03e-05	0.000116	CcSEcCtD
Levonorgestrel—Hydrocortisone—CYP3A4—breast cancer	1.03e-05	0.00375	CrCbGaD
Levonorgestrel—Discomfort—Doxorubicin—breast cancer	1.02e-05	0.000116	CcSEcCtD
Levonorgestrel—Anorexia—Epirubicin—breast cancer	1.02e-05	0.000116	CcSEcCtD
Levonorgestrel—Dyspnoea—Methotrexate—breast cancer	1.02e-05	0.000116	CcSEcCtD
Levonorgestrel—Somnolence—Methotrexate—breast cancer	1.02e-05	0.000115	CcSEcCtD
Levonorgestrel—Dizziness—Capecitabine—breast cancer	1.02e-05	0.000115	CcSEcCtD
Levonorgestrel—Vomiting—Docetaxel—breast cancer	1.01e-05	0.000114	CcSEcCtD
Levonorgestrel—Dyspepsia—Methotrexate—breast cancer	1.01e-05	0.000114	CcSEcCtD
Levonorgestrel—Rash—Docetaxel—breast cancer	1e-05	0.000113	CcSEcCtD
Levonorgestrel—Dermatitis—Docetaxel—breast cancer	1e-05	0.000113	CcSEcCtD
Levonorgestrel—Decreased appetite—Methotrexate—breast cancer	9.97e-06	0.000113	CcSEcCtD
Levonorgestrel—Headache—Docetaxel—breast cancer	9.97e-06	0.000113	CcSEcCtD
Levonorgestrel—Oedema—Doxorubicin—breast cancer	9.93e-06	0.000112	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Methotrexate—breast cancer	9.9e-06	0.000112	CcSEcCtD
Levonorgestrel—Fatigue—Methotrexate—breast cancer	9.89e-06	0.000112	CcSEcCtD
Levonorgestrel—Infection—Doxorubicin—breast cancer	9.87e-06	0.000112	CcSEcCtD
Levonorgestrel—Pain—Methotrexate—breast cancer	9.81e-06	0.000111	CcSEcCtD
Levonorgestrel—Vomiting—Capecitabine—breast cancer	9.8e-06	0.000111	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Epirubicin—breast cancer	9.78e-06	0.000111	CcSEcCtD
Levonorgestrel—Progesterone—CYP2D6—breast cancer	9.77e-06	0.00356	CrCbGaD
Levonorgestrel—Shock—Doxorubicin—breast cancer	9.77e-06	0.00011	CcSEcCtD
Levonorgestrel—Nervous system disorder—Doxorubicin—breast cancer	9.74e-06	0.00011	CcSEcCtD
Levonorgestrel—Rash—Capecitabine—breast cancer	9.71e-06	0.00011	CcSEcCtD
Levonorgestrel—Insomnia—Epirubicin—breast cancer	9.71e-06	0.00011	CcSEcCtD
Levonorgestrel—Dermatitis—Capecitabine—breast cancer	9.71e-06	0.00011	CcSEcCtD
Levonorgestrel—Headache—Capecitabine—breast cancer	9.65e-06	0.000109	CcSEcCtD
Levonorgestrel—Skin disorder—Doxorubicin—breast cancer	9.65e-06	0.000109	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Doxorubicin—breast cancer	9.6e-06	0.000109	CcSEcCtD
Levonorgestrel—Dyspnoea—Epirubicin—breast cancer	9.57e-06	0.000108	CcSEcCtD
Levonorgestrel—Somnolence—Epirubicin—breast cancer	9.54e-06	0.000108	CcSEcCtD
Levonorgestrel—Anorexia—Doxorubicin—breast cancer	9.47e-06	0.000107	CcSEcCtD
Levonorgestrel—Nausea—Docetaxel—breast cancer	9.45e-06	0.000107	CcSEcCtD
Levonorgestrel—Dyspepsia—Epirubicin—breast cancer	9.45e-06	0.000107	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Methotrexate—breast cancer	9.38e-06	0.000106	CcSEcCtD
Levonorgestrel—Decreased appetite—Epirubicin—breast cancer	9.33e-06	0.000105	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Epirubicin—breast cancer	9.27e-06	0.000105	CcSEcCtD
Levonorgestrel—Fatigue—Epirubicin—breast cancer	9.25e-06	0.000105	CcSEcCtD
Levonorgestrel—Pain—Epirubicin—breast cancer	9.18e-06	0.000104	CcSEcCtD
Levonorgestrel—Constipation—Epirubicin—breast cancer	9.18e-06	0.000104	CcSEcCtD
Levonorgestrel—Nausea—Capecitabine—breast cancer	9.15e-06	0.000103	CcSEcCtD
Levonorgestrel—Urticaria—Methotrexate—breast cancer	9.11e-06	0.000103	CcSEcCtD
Levonorgestrel—Body temperature increased—Methotrexate—breast cancer	9.07e-06	0.000102	CcSEcCtD
Levonorgestrel—Abdominal pain—Methotrexate—breast cancer	9.07e-06	0.000102	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Doxorubicin—breast cancer	9.05e-06	0.000102	CcSEcCtD
Levonorgestrel—Insomnia—Doxorubicin—breast cancer	8.98e-06	0.000102	CcSEcCtD
Levonorgestrel—Dyspnoea—Doxorubicin—breast cancer	8.85e-06	0.0001	CcSEcCtD
Levonorgestrel—Somnolence—Doxorubicin—breast cancer	8.83e-06	9.98e-05	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Epirubicin—breast cancer	8.78e-06	9.92e-05	CcSEcCtD
Levonorgestrel—Dyspepsia—Doxorubicin—breast cancer	8.74e-06	9.88e-05	CcSEcCtD
Levonorgestrel—Decreased appetite—Doxorubicin—breast cancer	8.63e-06	9.76e-05	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Doxorubicin—breast cancer	8.57e-06	9.69e-05	CcSEcCtD
Levonorgestrel—Hydrocortisone—ABCB1—breast cancer	8.56e-06	0.00312	CrCbGaD
Levonorgestrel—Fatigue—Doxorubicin—breast cancer	8.56e-06	9.68e-05	CcSEcCtD
Levonorgestrel—Urticaria—Epirubicin—breast cancer	8.53e-06	9.64e-05	CcSEcCtD
Levonorgestrel—Pain—Doxorubicin—breast cancer	8.49e-06	9.6e-05	CcSEcCtD
Levonorgestrel—Constipation—Doxorubicin—breast cancer	8.49e-06	9.6e-05	CcSEcCtD
Levonorgestrel—Abdominal pain—Epirubicin—breast cancer	8.48e-06	9.59e-05	CcSEcCtD
Levonorgestrel—Body temperature increased—Epirubicin—breast cancer	8.48e-06	9.59e-05	CcSEcCtD
Levonorgestrel—Hypersensitivity—Methotrexate—breast cancer	8.45e-06	9.55e-05	CcSEcCtD
Levonorgestrel—Progesterone—CYP3A4—breast cancer	8.38e-06	0.00305	CrCbGaD
Levonorgestrel—Asthenia—Methotrexate—breast cancer	8.23e-06	9.3e-05	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Doxorubicin—breast cancer	8.12e-06	9.18e-05	CcSEcCtD
Levonorgestrel—Pruritus—Methotrexate—breast cancer	8.11e-06	9.17e-05	CcSEcCtD
Levonorgestrel—Testosterone—CYP3A4—breast cancer	7.92e-06	0.00289	CrCbGaD
Levonorgestrel—Hypersensitivity—Epirubicin—breast cancer	7.91e-06	8.94e-05	CcSEcCtD
Levonorgestrel—Urticaria—Doxorubicin—breast cancer	7.89e-06	8.92e-05	CcSEcCtD
Levonorgestrel—Abdominal pain—Doxorubicin—breast cancer	7.85e-06	8.88e-05	CcSEcCtD
Levonorgestrel—Body temperature increased—Doxorubicin—breast cancer	7.85e-06	8.88e-05	CcSEcCtD
Levonorgestrel—Diarrhoea—Methotrexate—breast cancer	7.85e-06	8.87e-05	CcSEcCtD
Levonorgestrel—Asthenia—Epirubicin—breast cancer	7.7e-06	8.71e-05	CcSEcCtD
Levonorgestrel—Pruritus—Epirubicin—breast cancer	7.59e-06	8.58e-05	CcSEcCtD
Levonorgestrel—Dizziness—Methotrexate—breast cancer	7.58e-06	8.57e-05	CcSEcCtD
Levonorgestrel—Diarrhoea—Epirubicin—breast cancer	7.34e-06	8.3e-05	CcSEcCtD
Levonorgestrel—Hypersensitivity—Doxorubicin—breast cancer	7.32e-06	8.27e-05	CcSEcCtD
Levonorgestrel—Vomiting—Methotrexate—breast cancer	7.29e-06	8.24e-05	CcSEcCtD
Levonorgestrel—Rash—Methotrexate—breast cancer	7.23e-06	8.18e-05	CcSEcCtD
Levonorgestrel—Dermatitis—Methotrexate—breast cancer	7.22e-06	8.17e-05	CcSEcCtD
Levonorgestrel—Headache—Methotrexate—breast cancer	7.19e-06	8.12e-05	CcSEcCtD
Levonorgestrel—Asthenia—Doxorubicin—breast cancer	7.13e-06	8.06e-05	CcSEcCtD
Levonorgestrel—Dizziness—Epirubicin—breast cancer	7.1e-06	8.02e-05	CcSEcCtD
Levonorgestrel—Pruritus—Doxorubicin—breast cancer	7.03e-06	7.94e-05	CcSEcCtD
Levonorgestrel—Progesterone—ABCB1—breast cancer	6.98e-06	0.00254	CrCbGaD
Levonorgestrel—Testosterone—ALB—breast cancer	6.91e-06	0.00252	CrCbGaD
Levonorgestrel—Vomiting—Epirubicin—breast cancer	6.82e-06	7.72e-05	CcSEcCtD
Levonorgestrel—Nausea—Methotrexate—breast cancer	6.81e-06	7.7e-05	CcSEcCtD
Levonorgestrel—Diarrhoea—Doxorubicin—breast cancer	6.8e-06	7.68e-05	CcSEcCtD
Levonorgestrel—Rash—Epirubicin—breast cancer	6.77e-06	7.65e-05	CcSEcCtD
Levonorgestrel—Dermatitis—Epirubicin—breast cancer	6.76e-06	7.64e-05	CcSEcCtD
Levonorgestrel—Headache—Epirubicin—breast cancer	6.72e-06	7.6e-05	CcSEcCtD
Levonorgestrel—Testosterone—ABCB1—breast cancer	6.6e-06	0.0024	CrCbGaD
Levonorgestrel—Dizziness—Doxorubicin—breast cancer	6.57e-06	7.42e-05	CcSEcCtD
Levonorgestrel—Nausea—Epirubicin—breast cancer	6.38e-06	7.21e-05	CcSEcCtD
Levonorgestrel—Vomiting—Doxorubicin—breast cancer	6.31e-06	7.14e-05	CcSEcCtD
Levonorgestrel—Rash—Doxorubicin—breast cancer	6.26e-06	7.08e-05	CcSEcCtD
Levonorgestrel—Dermatitis—Doxorubicin—breast cancer	6.26e-06	7.07e-05	CcSEcCtD
Levonorgestrel—Headache—Doxorubicin—breast cancer	6.22e-06	7.03e-05	CcSEcCtD
Levonorgestrel—Nausea—Doxorubicin—breast cancer	5.9e-06	6.67e-05	CcSEcCtD
Levonorgestrel—ESR1—Signaling Pathways—FLT1—breast cancer	2.89e-06	5.38e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGF3—breast cancer	2.88e-06	5.35e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SQSTM1—breast cancer	2.88e-06	5.35e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CAV1—breast cancer	2.87e-06	5.35e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ABCB1—breast cancer	2.85e-06	5.3e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—JAG1—breast cancer	2.84e-06	5.29e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KDR—breast cancer	2.84e-06	5.29e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NOTCH3—breast cancer	2.83e-06	5.26e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PARP1—breast cancer	2.83e-06	5.26e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—TYMS—breast cancer	2.79e-06	5.2e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CALCA—breast cancer	2.79e-06	5.2e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ESR1—breast cancer	2.77e-06	5.15e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PLA2G4A—breast cancer	2.76e-06	5.14e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GSTM1—breast cancer	2.76e-06	5.14e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—NCOR1—breast cancer	2.76e-06	5.14e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RPS6—breast cancer	2.76e-06	5.14e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGF4—breast cancer	2.74e-06	5.1e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FN1—breast cancer	2.73e-06	5.09e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL12—breast cancer	2.73e-06	5.08e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCR4—breast cancer	2.73e-06	5.08e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CDA—breast cancer	2.72e-06	5.07e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SHMT1—breast cancer	2.72e-06	5.07e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NFKBIA—breast cancer	2.7e-06	5.03e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—MYC—breast cancer	2.7e-06	5.02e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PAK1—breast cancer	2.68e-06	4.98e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NOTCH1—breast cancer	2.68e-06	4.98e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—SERPINE1—breast cancer	2.67e-06	4.96e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GPX1—breast cancer	2.65e-06	4.92e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TCF7L2—breast cancer	2.63e-06	4.9e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC2A5—breast cancer	2.62e-06	4.88e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLCO1B1—breast cancer	2.62e-06	4.88e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CYP1A1—breast cancer	2.62e-06	4.87e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—APC—breast cancer	2.62e-06	4.87e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CG—breast cancer	2.62e-06	4.87e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KIT—breast cancer	2.62e-06	4.87e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ERCC2—breast cancer	2.6e-06	4.83e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGF—breast cancer	2.59e-06	4.81e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HSP90AA1—breast cancer	2.54e-06	4.72e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NOTCH2—breast cancer	2.54e-06	4.72e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—APRT—breast cancer	2.53e-06	4.71e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PRL—breast cancer	2.47e-06	4.59e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AGTR1—breast cancer	2.47e-06	4.59e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—BRAF—breast cancer	2.46e-06	4.58e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—MTHFR—breast cancer	2.44e-06	4.54e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—STK11—breast cancer	2.43e-06	4.53e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ADAM10—breast cancer	2.43e-06	4.53e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—NOTCH1—breast cancer	2.42e-06	4.49e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PLG—breast cancer	2.4e-06	4.48e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IGF1—breast cancer	2.4e-06	4.46e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKT2—breast cancer	2.39e-06	4.46e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ANGPTL4—breast cancer	2.38e-06	4.43e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ESRRA—breast cancer	2.38e-06	4.43e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGF10—breast cancer	2.37e-06	4.4e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CD—breast cancer	2.3e-06	4.28e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PDGFA—breast cancer	2.28e-06	4.25e-05	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MAPK3—breast cancer	2.28e-06	4.24e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SERPINE1—breast cancer	2.27e-06	4.23e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HADHB—breast cancer	2.26e-06	4.2e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GPI—breast cancer	2.26e-06	4.2e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CAV1—breast cancer	2.25e-06	4.19e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TGFBR2—breast cancer	2.25e-06	4.19e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ITPR1—breast cancer	2.21e-06	4.12e-05	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MYC—breast cancer	2.21e-06	4.12e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB4—breast cancer	2.2e-06	4.09e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—STAT5A—breast cancer	2.2e-06	4.09e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MMP3—breast cancer	2.2e-06	4.09e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NOS3—breast cancer	2.17e-06	4.04e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ALDH1A1—breast cancer	2.15e-06	4.01e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ALDH7A1—breast cancer	2.15e-06	4.01e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.15e-06	4e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SMAD4—breast cancer	2.13e-06	3.96e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IGF1R—breast cancer	2.12e-06	3.94e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HES1—breast cancer	2.08e-06	3.87e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NCOR1—breast cancer	2.07e-06	3.85e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PLA2G4A—breast cancer	2.07e-06	3.85e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NME1—breast cancer	2.06e-06	3.84e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—FHL2—breast cancer	2.06e-06	3.84e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ADSL—breast cancer	2.06e-06	3.84e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PHGDH—breast cancer	2.06e-06	3.84e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—UMPS—breast cancer	2.06e-06	3.84e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MDM2—breast cancer	2.06e-06	3.84e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—SERPINE1—breast cancer	2.05e-06	3.82e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—RAF1—breast cancer	2.05e-06	3.82e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CG—breast cancer	2.05e-06	3.82e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CSF2—breast cancer	2.04e-06	3.81e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGF1—breast cancer	2.04e-06	3.81e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—RELA—breast cancer	2.04e-06	3.8e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ERBB2—breast cancer	2.03e-06	3.78e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NRG1—breast cancer	2.03e-06	3.78e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HPSE—breast cancer	2.03e-06	3.77e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—BRIP1—breast cancer	2.03e-06	3.77e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—LDHB—breast cancer	2.03e-06	3.77e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—H2AFX—breast cancer	2.02e-06	3.75e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MTOR—breast cancer	2e-06	3.73e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CB—breast cancer	2e-06	3.73e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—E2F1—breast cancer	2e-06	3.72e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCL8—breast cancer	1.93e-06	3.59e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SPP1—breast cancer	1.92e-06	3.58e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HMMR—breast cancer	1.92e-06	3.57e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTA3—breast cancer	1.92e-06	3.57e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ABCC1—breast cancer	1.92e-06	3.57e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB3—breast cancer	1.9e-06	3.54e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGFR2—breast cancer	1.9e-06	3.53e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN1B—breast cancer	1.88e-06	3.5e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PPARGC1B—breast cancer	1.86e-06	3.46e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CASP3—breast cancer	1.84e-06	3.43e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL2—breast cancer	1.84e-06	3.43e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TERT—breast cancer	1.82e-06	3.39e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CD—breast cancer	1.8e-06	3.36e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCND1—breast cancer	1.79e-06	3.34e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—JUN—breast cancer	1.79e-06	3.33e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ALB—breast cancer	1.78e-06	3.31e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CTNNB1—breast cancer	1.78e-06	3.31e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGFR1—breast cancer	1.77e-06	3.29e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTA4—breast cancer	1.76e-06	3.27e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CA9—breast cancer	1.76e-06	3.27e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HIF1A—breast cancer	1.74e-06	3.24e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MMP9—breast cancer	1.74e-06	3.24e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN1A—breast cancer	1.74e-06	3.23e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MAPK3—breast cancer	1.73e-06	3.23e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTEN—breast cancer	1.73e-06	3.22e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GPX2—breast cancer	1.71e-06	3.18e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTA2—breast cancer	1.71e-06	3.18e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—NOS3—breast cancer	1.7e-06	3.17e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—LEP—breast cancer	1.7e-06	3.17e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MAPK8—breast cancer	1.69e-06	3.15e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SULT1A1—breast cancer	1.69e-06	3.15e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GPX4—breast cancer	1.69e-06	3.15e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MYC—breast cancer	1.69e-06	3.14e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CAV1—breast cancer	1.69e-06	3.14e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KDR—breast cancer	1.67e-06	3.1e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—IDH1—breast cancer	1.65e-06	3.07e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTA1—breast cancer	1.65e-06	3.07e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NAT2—breast cancer	1.63e-06	3.04e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SRC—breast cancer	1.61e-06	2.99e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FN1—breast cancer	1.6e-06	2.99e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NFKBIA—breast cancer	1.59e-06	2.95e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CB—breast cancer	1.57e-06	2.93e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NOTCH1—breast cancer	1.57e-06	2.92e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—VEGFA—breast cancer	1.56e-06	2.91e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTGS2—breast cancer	1.56e-06	2.9e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—STAT3—breast cancer	1.55e-06	2.88e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CG—breast cancer	1.54e-06	2.86e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—APC—breast cancer	1.54e-06	2.86e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KIT—breast cancer	1.54e-06	2.86e-05	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—AKT1—breast cancer	1.54e-06	2.86e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGF—breast cancer	1.52e-06	2.82e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MAPK3—breast cancer	1.48e-06	2.75e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—BRAF—breast cancer	1.44e-06	2.69e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MYC—breast cancer	1.44e-06	2.68e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TGFB1—breast cancer	1.44e-06	2.67e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MED12—breast cancer	1.43e-06	2.66e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—DPYD—breast cancer	1.43e-06	2.66e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ALDOA—breast cancer	1.41e-06	2.62e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGFR—breast cancer	1.41e-06	2.62e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IGF1—breast cancer	1.41e-06	2.62e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKT2—breast cancer	1.4e-06	2.61e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NCOA3—breast cancer	1.37e-06	2.55e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC2A2—breast cancer	1.36e-06	2.53e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTEN—breast cancer	1.36e-06	2.53e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CD—breast cancer	1.35e-06	2.51e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MAPK3—breast cancer	1.34e-06	2.49e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SERPINE1—breast cancer	1.34e-06	2.48e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CPT1A—breast cancer	1.33e-06	2.48e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MTR—breast cancer	1.33e-06	2.48e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ABCG2—breast cancer	1.33e-06	2.48e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KRAS—breast cancer	1.33e-06	2.48e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HPGDS—breast cancer	1.3e-06	2.43e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MYC—breast cancer	1.3e-06	2.42e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HBA1—breast cancer	1.3e-06	2.41e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NOS3—breast cancer	1.27e-06	2.37e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ACHE—breast cancer	1.27e-06	2.36e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTT1—breast cancer	1.27e-06	2.36e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CA—breast cancer	1.22e-06	2.27e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MDM2—breast cancer	1.21e-06	2.25e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RAF1—breast cancer	1.21e-06	2.24e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RELA—breast cancer	1.2e-06	2.23e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP17A1—breast cancer	1.2e-06	2.23e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB2—breast cancer	1.19e-06	2.22e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTGS1—breast cancer	1.19e-06	2.21e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ENO1—breast cancer	1.19e-06	2.21e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—breast cancer	1.18e-06	2.2e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MTOR—breast cancer	1.18e-06	2.19e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CB—breast cancer	1.18e-06	2.19e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—AKT1—breast cancer	1.17e-06	2.18e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP2D6—breast cancer	1.16e-06	2.16e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NCOA2—breast cancer	1.14e-06	2.12e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL8—breast cancer	1.13e-06	2.1e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HRAS—breast cancer	1.13e-06	2.1e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—FASN—breast cancer	1.11e-06	2.06e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN1B—breast cancer	1.1e-06	2.06e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—BCHE—breast cancer	1.1e-06	2.05e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC5A5—breast cancer	1.09e-06	2.03e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CASP3—breast cancer	1.08e-06	2.01e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL6—breast cancer	1.08e-06	2.01e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL2—breast cancer	1.08e-06	2.01e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCND1—breast cancer	1.05e-06	1.96e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC2A1—breast cancer	1.05e-06	1.96e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NQO1—breast cancer	1.05e-06	1.96e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—JUN—breast cancer	1.05e-06	1.96e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CTNNB1—breast cancer	1.04e-06	1.94e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MMP9—breast cancer	1.02e-06	1.9e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN1A—breast cancer	1.02e-06	1.9e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTEN—breast cancer	1.02e-06	1.89e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP1B1—breast cancer	1.01e-06	1.88e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKT1—breast cancer	9.98e-07	1.86e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAPK8—breast cancer	9.95e-07	1.85e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HSP90AA1—breast cancer	9.89e-07	1.84e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NCOA1—breast cancer	9.62e-07	1.79e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CA—breast cancer	9.58e-07	1.78e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—STK11—breast cancer	9.48e-07	1.76e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP19A1—breast cancer	9.48e-07	1.76e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SRC—breast cancer	9.43e-07	1.75e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VEGFA—breast cancer	9.18e-07	1.71e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—STAT3—breast cancer	9.09e-07	1.69e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—AKT1—breast cancer	9.01e-07	1.68e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—COMT—breast cancer	8.81e-07	1.64e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTP1—breast cancer	8.77e-07	1.63e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAPK3—breast cancer	8.69e-07	1.62e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HMOX1—breast cancer	8.65e-07	1.61e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ITPR1—breast cancer	8.63e-07	1.61e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MYC—breast cancer	8.45e-07	1.57e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TGFB1—breast cancer	8.43e-07	1.57e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ABCB1—breast cancer	8.3e-07	1.55e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGFR—breast cancer	8.26e-07	1.54e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TYMS—breast cancer	8.16e-07	1.52e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NCOR1—breast cancer	8.06e-07	1.5e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTM1—breast cancer	8.06e-07	1.5e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PLA2G4A—breast cancer	8.06e-07	1.5e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—AKT1—breast cancer	7.83e-07	1.46e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KRAS—breast cancer	7.81e-07	1.45e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GPX1—breast cancer	7.72e-07	1.44e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP1A1—breast cancer	7.64e-07	1.42e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ERCC2—breast cancer	7.58e-07	1.41e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CA—breast cancer	7.17e-07	1.33e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MTHFR—breast cancer	7.12e-07	1.33e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—breast cancer	6.94e-07	1.29e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HRAS—breast cancer	6.64e-07	1.24e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CAV1—breast cancer	6.57e-07	1.22e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL6—breast cancer	6.35e-07	1.18e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CG—breast cancer	5.99e-07	1.11e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKT1—breast cancer	5.86e-07	1.09e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CD—breast cancer	5.26e-07	9.79e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ALB—breast cancer	5.2e-07	9.67e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NOS3—breast cancer	4.97e-07	9.25e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CB—breast cancer	4.59e-07	8.54e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTGS2—breast cancer	4.54e-07	8.46e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTEN—breast cancer	3.96e-07	7.38e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CA—breast cancer	2.8e-07	5.2e-06	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKT1—breast cancer	2.28e-07	4.25e-06	CbGpPWpGaD
